X4 Pharmaceuticals Inc (XFOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $288.98M
Last updated: Nov 17, 2026 at 4:33 PM ET
X4 Pharmaceuticals Inc (XFOR) Statistics
X4 Pharmaceuticals (XFOR) has a market cap of $288.98M and an enterprise value of $180.19M. Its share count is up 192.39% from a year earlier. It kept -487.03% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 37.65% below the market cap, as cash exceeds debt.
| Market Cap | $288.98M |
|---|---|
| Enterprise Value | $180.19M |
| Latest price (Nov 17, 2026) | $3.09 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 23.6x and 2.8x. Its year-end P/S ranged from 0.9x to 190.3x from 2019 to 2025.
| P/S Ratio | 23.6x |
|---|---|
| Forward P/S | 16.8x |
| P/B Ratio | 2.8x |
| P/TBV Ratio | 3.6x |
Price Statistics
The stock is down 15.57% over 52 weeks and trades 0.96% below its 50-day average.
| Beta (1Y) | 1.59 |
|---|---|
| 52-Week Change | -15.57% |
| 1-Month Change | +12.36% |
| 3-Month Change | -25.72% |
| 6-Month Change | -15.11% |
| 5-Year Change | -97.70% |
| Total Return (1Y) | -15.57% |
| Total Return (3Y CAGR) | -49.42% |
| Total Return (5Y CAGR) | -53.66% |
| Return vs SPY (1Y) | -25.73% |
| Max Drawdown (1Y) | -47.54% |
| Max Drawdown (3Y) | -96.78% |
| Sharpe Ratio (1Y) | -0.21 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $3.12 |
| 200-Day Average | $3.77 |
| 52-Week Range | $2.43 to $4.83 |
| RSI (14 Days) | 48.2 |
| Average Volume (20 Days) | 770.49K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 13.22x current liabilities, and total debt is 0.55x shareholder equity.
| Current Ratio | 13.22x |
|---|---|
| Quick Ratio | 12.86x |
| Debt / Equity | 0.55x |
| Interest Coverage | -9.19x |
Returns and Efficiency
Return on invested capital is -36.93% over the last 12 months, against a 5-year average of -66.09%.
| Return on Equity (ROE) | -57.98% |
|---|---|
| Return on Assets (ROA) | -34.73% |
| Return on Invested Capital (ROIC) | -36.93% |
| Return on Capital Employed (ROCE) | -36.77% |
| ROA (5Y Average) | -51.51% |
| ROIC (5Y Average) | -66.09% |
| Asset Turnover | 0.08x |
| Inventory Turnover | 0.56x |
| Receivables Turnover | 9.40x |
| Cash Conversion Cycle | 168 days |
Scores
XFOR has an Altman Z-Score of -1.52, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.52 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $16.53M over the last 12 months is down 51.34% from the 12 months before.
| Revenue | $16.53M |
|---|---|
| Revenue Growth (YoY) | -51.34% |
| Gross Profit | $13.44M |
| Operating Income | -$80.39M |
| Pretax Income | -$80.52M |
| Net Income | -$80.52M |
| EBITDA | -$77.95M |
| EBIT | -$79.73M |
| Reported EPS (TTM) | -$0.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 59.91% of the $231.82M in total assets.
| Cash and Equivalents | $185.80M |
|---|---|
| Total Debt | $77.01M |
| Net Cash | $108.79M |
| Net Cash Per Share | $0.86 |
| Working Capital | $183.15M |
| Shareholder Equity | $138.88M |
| Book Value Per Share | $1.10 |
| Tangible Book Value | $108.71M |
| Tangible Book Per Share | $0.86 |
| Total Assets | $231.82M |
| Total Liabilities | $92.93M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$76.10M |
|---|---|
| FCF Per Share | -$1.00 |
| Depreciation and Amortization | $1.77M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -486.22%.
| Gross Margin | 81.30% |
|---|---|
| Operating Margin | -486.22% |
| Pretax Margin | -487.00% |
| Net Margin | -487.03% |
| EBITDA Margin | -471.51% |
| EBIT Margin | -482.24% |
Growth
| Revenue Growth (5Y CAGR) | +68.79% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -53.26% |
| Tangible Book Per Share Growth (2Y CAGR) | -46.75% |
Dividends and Yields
XFOR does not pay a dividend.
| Buyback Yield | -37.39% |
|---|---|
| Shareholder Yield | -37.39% |
Stock Splits
The last split was a 1-for-30 reverse split on Apr 28, 2025.
| Last Split Date | Apr 28, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 6 similar companies, XFOR has the 2nd highest P/S.
P/S RatioPeer median 5.5x
ROICPeer median -6.74%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -85.57%
| P/S Ratio | 23.6x vs 5.5x median |
|---|---|
| ROIC | -36.93% vs -6.74% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -51.34% vs -85.57% median |
Analyst Forecast
Consensus estimates put revenue growth at -42.42% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -42.42% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About XFOR
What is XFOR's market cap?
X4 Pharmaceuticals has a market cap of $288.98M. Its enterprise value, which adds debt and subtracts cash, is $180.19M.
How many shares of XFOR are outstanding?
X4 Pharmaceuticals has 126.52M shares outstanding. The count is up 192.39% from a year earlier.
Does XFOR pay a dividend?
No. X4 Pharmaceuticals does not pay a dividend.
How much debt does XFOR have?
X4 Pharmaceuticals has $77.01M of total debt and $185.80M of cash and equivalents, a net cash position of $108.79M.
XFOR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors